|
🐜
|
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
7 auth.
J. Cuzick,
I. Šestak,
M. Baum,
A. Buzdar,
A. Howell,
M. Dowsett,
...
J. Forbes
|
10 |
2010 |
10
🐜
|
|
🐜
|
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
10 auth.
M. Dowsett,
I. Šestak,
E. López-Knowles,
K. Sidhu,
A. Dunbier,
J. Cowens,
...
S. Ferree,
J. Storhoff,
C. Schaper,
J. Cuzick
|
9 |
2013 |
9
🐜
|
|
🐜
|
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial
13 auth.
J. Cuzick,
I. Šestak,
J. Forbes,
M. Dowsett,
Jill Knox,
S. Cawthorn,
C. Saunders,
N. Roche,
R. Mansel,
G. Minckwitz,
...
B. Bonanni,
T. Palva,
A. Howell
|
9 |
2014 |
9
🐜
|
|
🐜
|
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
7 auth.
J. Cuzick,
J. Forbes,
I. Šestak,
S. Cawthorn,
H. Hamed,
K. Holli,
...
A. Howell
|
9 |
2007 |
9
🐜
|
|
🐜
|
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
10 auth.
J. Cuzick,
I. Šestak,
S. Pinder,
I. Ellis,
S. Forsyth,
N. Bundred,
...
J. Forbes,
H. Bishop,
I. Fentiman,
W. George
|
9 |
2010 |
9
🐜
|
|
🐜
|
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
16 auth.
J. Cuzick,
I. Šestak,
B. Bonanni,
J. Costantino,
S. Cummings,
A. Decensi,
M. Dowsett,
J. Forbes,
L. Ford,
A. LaCroix,
...
J. Mershon,
B. Mitlak,
T. Powles,
U. Veronesi,
V. Vogel,
D. Wickerham
|
8 |
2013 |
8
🐜
|
|
🐜
|
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
19 auth.
B. Wallden,
J. Storhoff,
T. Nielsen,
N. Dowidar,
C. Schaper,
S. Ferree,
Shuzhen Liu,
S. Leung,
G. Geiss,
J. Snider,
...
T. Vickery,
S. Davies,
E. Mardis,
M. Gnant,
I. Šestak,
M. Ellis,
C. Perou,
P. Bernard,
J. Parker
|
8 |
2015 |
8
🐜
|
|
🐜
|
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
12 auth.
D. Sgroi,
I. Šestak,
J. Cuzick,
Yi Zhang,
C. Schnabel,
B. Schroeder,
...
M. Erlander,
A. Dunbier,
Kally Sidhu,
E. López-Knowles,
P. Goss,
M. Dowsett
|
8 |
2013 |
8
🐜
|
|
🐜
|
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial
7 auth.
J. Cuzick,
I. Šestak,
S. Cawthorn,
H. Hamed,
K. Holli,
A. Howell,
...
J. Forbes
|
8 |
2015 |
8
🐜
|
|
🦁
|
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
I. Šestak,
W. Distler,
J. Forbes,
M. Dowsett,
A. Howell,
J. Cuzick
|
8 |
2010 |
8
🦁
|
|
🦁
|
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer
12 auth.
I. Šestak,
R. Buus,
J. Cuzick,
P. Dubsky,
R. Kronenwett,
C. Denkert,
...
S. Ferree,
D. Sgroi,
C. Schnabel,
F. Baehner,
E. Mallon,
M. Dowsett
|
8 |
2018 |
8
🦁
|
|
🐜
|
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
10 auth.
J. Rae,
S. Drury,
D. Hayes,
V. Stearns,
Jacklyn N. Thibert,
B. Haynes,
...
J. Salter,
I. Šestak,
J. Cuzick,
M. Dowsett
|
7 |
2012 |
7
🐜
|
